Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Langetermijnresultaten van SABR bij operabel stadium I NSCLC
dec 2021 | Chirurgie, Longoncologie, Radiotherapie